Angiogenesis as a Therapeutic Target in Malignant Gliomas

被引：91

作者：

Chi, Andrew S. ^{[1
,4
]}

Sorensen, A. Gregory ^{[2
,4
]}

Jain, Rakesh K. ^{[3
,4
]}

Batchelor, Tracy T. ^{[1
,4
]}

机构：

[1] Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Ctr Canc, Div Hematol & Oncol,Dept Neurol, Boston, MA 02114 USA

[2] AA Martinos Ctr Biomed Imaging, Boston, MA USA

[3] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA

[4] Harvard Univ, Sch Med, Boston, MA USA

来源：

ONCOLOGIST | 2009年 / 14卷 / 06期

关键词：

Malignant glioma; Glioblastoma; Angiogenesis; Vascular endothelial growth factor; Cerebral edema; ENDOTHELIAL-GROWTH-FACTOR; PHASE-II TRIAL; NEWLY-DIAGNOSED GLIOBLASTOMA; BEVACIZUMAB PLUS IRINOTECAN; LOW-DOSE CHEMOTHERAPY; INHIBITS TUMOR-GROWTH; HIGH-GRADE GLIOMAS; RADIATION-THERAPY; ANTIANGIOGENIC THERAPY; IMATINIB MESYLATE;

D O I：

10.1634/theoncologist.2008-0272

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Currently, adult glioblastoma (GBM) patients have poor outcomes with conventional cytotoxic treatments. Because GBMs are highly angiogenic tumors, inhibitors that target tumor vasculature are considered promising therapeutic agents in these patients. Encouraging efficacy and tolerability in preliminary clinical trials suggest that targeting angiogenesis may be an effective therapeutic strategy in GBM patients. However, the survival benefits observed to date in uncontrolled trials of antiangiogenic agents have been modest, and several obstacles have limited their effectiveness. This article reviews the rationale for antiangiogenic agents in GBM, their potential mechanisms of action, and their clinical development in GBM patients. Although challenges remain with this approach, ongoing studies may improve upon the promising initial benefits already observed in GBM patients. The Oncologist 2009; 14: 621-636

引用

页码：621 / 636

页数：16

共 177 条

[71] Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth [J].